Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Kent, Shia T ^a   Shimbo, Daichi ^b   Huang, Lei ^a   Diaz, Keith M ^b   Kilgore, Meredith L ^a   Oparil, Suzanne ^c   Muntner, Paul ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Department of Medicine   (United States)

^c University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLACK PERSON; CAUCASIAN; COHORT ANALYSIS; DRUG USE; ETHNIC DIFFERENCE; HEALTH INSURANCE; HYPERTENSION; MEDICARE; OUTPATIENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SEX DIFFERENCE; AGED; CLASSIFICATION; CLINICAL PRACTICE; FEMALE; HUMAN; MALE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MEDICARE; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84925663443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105888     Document Type: Article

References (23)

1. Allhat Officers and Coordinators for the Allhat Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572. doi: 10.1001/jama.289.19.2560. (Pubitemid 37430158)
3. Xie F, Petitti DB, Chen W (2005) Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens 18: 464-469. doi: 10.1016/j.amjhyper.2004.11.004.
4. Muntner P, Krousel-Wood M, Hyre AD, Stanley E, Cushman WC, et al. (2009) Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. Hypertension 53: 617-623. doi: 10.1161/HYPERTENSIONAHA.108.120154.
5. Player MS, Gill JM, Fagan HB, Mainous AG, 3rd (2006) Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens (Greenwich) 8: 860-864.
6. Bian B, Kelton CM, Guo JJ, Wigle PR (2010) ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm 16: 671-679.
7. Brendt ER, Aitken ML (2011) Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation. Int J Econ Bus 18: 177-201.
8. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417-2428. doi: 10.1056/NEJMoa0806182.
9. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665. doi: 10.1136/bmj.b1665.
10. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, et al. (2003) Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289: 2073-2082. doi: 10.1001/ jama.289.16.2073.
11. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, et al. (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592. doi: 10.1056/NEJMoa021716. (Pubitemid 36204952)
12. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, et al. (2003) Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 12: 160-167. (Pubitemid 36874765)
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187. doi: 10.1097/HJH.0b013e3281fc975a. (Pubitemid 46924065)
14. Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983-1992. doi: 10.1097/01.hjh. 0000084751.37215.d2.
15. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, et al. (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761-2788. doi: 10.1161/CIRCULATIONAHA.107.183885. (Pubitemid 46842793)
16. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al. (2013) 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. December 18, 2013 ed.
17. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, et al. (2012) Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59: 1124-1131. doi: 10.1161/HYPERTENSIONAHA.112.194167.
18. Gu Q, Burt VL, Dillon CF, Yoon S (2012) Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 126: 2105-2114. doi: 10.1161/CIRCULATIONAHA.112.096156.
19. Krousel-Wood M, Muntner P, Carson A, Anderson AH, Delaune E, et al. (2012) Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich) 14: 277-283. doi: 10.1111/j.1751-7176.2012.00609.x.
20. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, et al. (2011) Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 57: 1101-1107. doi:10.1161/HYPERTENSIONAHA.110.168005.
21. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Heart disease and stroke statistics-2014 update: a report from the american heart association. Circulation 129: e28-e292. doi: 10.1161/01.cir.0000441139. 02102.80.
22. Vlasschaert ME, Bejaimal SA, Hackam DG, Quinn R, Cuerden MS, et al. (2011) Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis 57: 29-43. doi: 10.1053/j.ajkd.2010.08.031.
23. Yun H, Curtis JR, Saag K, Kilgore M, Muntner P, et al. (2013) Generic alendronate use among Medicare beneficiaries: are Part D data complete? Pharmacoepidemiol Drug Saf 22: 55-63. doi: 10.1002/pds.3361.